Deal Snapshot: Roche is finally returning the rights to two failed Alzheimer’s candidates. But why now?
Who: Roche Holding AG/AC Immune SA
What: Roche has returned all global rights to the anti-amyloid beta antibody crenezumab and the anti-Tau antibody semorinemab to their...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
The Danish firm’s board unanimously supports a $2bn take-private offer by PE firms Nordic Capital and Permira. A revised offer would seek to bypass the opposition of a major shareholder.
The Swiss giant is paying $30m upfront for rights to the Swedish firm’s BrainTransporter technology, its second brain-barrier breaching deal in as many months.
Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.
The CAR-T specialist is spending $350m to acquire the private Philadelphia-based firm, which is developing in vivo CAR-Ts using lentiviral vectors.
After an Aug. 6 safety labeling change, the FDA became aware of “more compelling evidence” that the risk for serious chikungunya-like illness is not limited to older adults, CBER Director Prasad said.
BeOne could realize up to $950m under a deal with Royalty Pharma for its portion of sales from Amgen’s DLL3 inhibitor. Also, Novavax refinanced convertible debt, Kriya Therapeutics raised $313.3m in venture capital and Vaxxas garnered A$89.2m ($57.9m) in venture debt and cash.
Partnered since May 2024, AbbVie and Gilgamesh agreed on a deal in which AbbVie will buy bretisilocin for up to $1.2bn, while Gilgamesh will spin out its remaining pipeline.
